Viral Diversity an Innovative Biomarker for Refining Estimates of HIV Incidence

病毒多样性是改进艾滋病毒发病率估计的创新生物标志物

• 批准号: 10538707
• 负责人: Sikhulile Moyo
• 金额: $ 13.65万
• 依托单位: BOTSWANA-HARVARD AIDS INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-08-01 至 2027-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10538707
• 关键词: 2019-nCoV; AIDS prevention; Adopted; Advisory Committees; African; Algorithms; Area; Bioinformatics; Biological Assay; Biological Markers; Biometry; Country; Cross-Sectional Studies; Data; Development; Development Plans; Epidemic; Epidemiology; Evaluation; Exclusion; Genetic Recombination; Genome; Genomics; Genotype; HIV; HIV Genome; HIV Infections; HIV-1; Incidence; Individual; Infection; Institution; Intervention; Laboratories; Lead; Leadership; Length; Longitudinal Studies; Measurement; Measures; Mentors; Mentorship; Methodology; Methods; Modeling; Molecular; Molecular Epidemiology; Monitor; Outcome; Patients; Persons; Phylogenetic Analysis; Policy Maker; Population; Prevention Research; Process; Public Health; RNA; Research; Research Personnel; Research Project Grants; Resource-limited setting; Role; Sampling; Sensitivity and Specificity; Serology; Specificity; Specimen; Students; Supervision; Surveys; Testing; Time; Training; Training Activity; Uncertainty; Viral; Viral Genome; Virus; Virus Replication; antiretroviral therapy; bioinformatics pipeline; career; career development; cost; cost effective; experience; genome sequencing; improved; innovation; longitudinal analysis; low income country; next generation sequencing; potential biomarker; practical application; pre-exposure prophylaxis; programs; prospective; public health emergency; research study; response; scale up; screening; seroconversion; skills; tool; transmission process; trend

Project Summary Candidate: Dr Sikhulile Moyo is unwaveringly committed to an overarching career focused on contributing to ending the HIV epidemic and related public health emergencies. He committed to a career focused on finding cost-effective tools for estimating the impact of interventions and towards HIV cure research. He envisions himself as a leader globally, in research aimed towards tracking and eliminating new HIV infections & towards developing an HIV cure, working with researchers, program implementers and policy makers for rapid and cost-effective evaluation of interventions. Dr Moyo’s 5-year career development plan is focused on three key areas: phylogenetics, epidemiology and biostatistics; cross-sectional Incidence and Implementation; and HIV cure & characterization of early founder viruses, and SARS-COV-2 genomics. In order to achieve his short- and medium-term career objectives he seeks to: a) develop advanced methodologic and analytic skills in molecular epidemiology, phylogenetic analysis and bioinformatics; b) expand laboratory expertise in real-time high-throughput next generation sequencing and accurate and reliable quantification of proviral reservoirs for advancing HIV cure studies, and c) strengthen leadership abilities particularly in managing large scientific projects, population-level surveys, and diverse research teams with expertise in different fields, organizational leadership and student research supervision. Training activities will encompass formal training and coursework, practical application through the proposed research project, and direct mentorship from my highly experienced mentorship and advisory team. These activities will draw on the strengths of the mentorship team and leading research institutions with strong collaborative ties and have a record of mentoring young investigators to R01 and independence. Research: The study aims to introduce an innovative approach to estimating HIV incidence, which is very important for national HIV programs / public health, and also for HIV prevention research, but can be expensive and challenging to do. The specific aims are: 1) To assess adjusted viral diversity as a potential biomarker of HIV incidence. 2) To refine results of serological screening in subsets of true- and false-recent cases, and patients with established infection (ART-naïve and on ART), by adjusted viral diversity. We will test whether viral diversity within the most informative regions across the HIV-1C genome adjusted for multiplicity of transmission, recombination, and level of viral replication could be used to refine the results of serological screening and improve specificity and sensitivity. We expect that the adjusted viral diversity within the most informative regions will increase specificity and sensitivity in estimation of HIV incidence within the 4 subsets of individuals targeted in this Aim to ≥95%. Establishing a cost-effective algorithm to estimate incidence is of critical public health importance in low resource settings.

项目摘要 候选人：Sikhulile Moyo博士坚定地致力于致力于贡献的总体职业 结束艾滋病毒流行和相关的公共卫生紧急情况。他承诺从事专注于寻找的职业 具有成本效益的工具，用于估计干预措施和对HIV治疗研究的影响。他设想 他本人是全球领导者，旨在追踪和消除新的艾滋病毒感染并朝着 开发艾滋病毒治愈方法，与研究人员，计划实施者和政策制定者合作，以实现快速和政策制定者 干预措施的成本效益评估。 Moyo博士的5年职业发展计划集中在三个关键上 区域：系统发育学，流行病学和生物统计学；横断面事件和实施；和艾滋病毒 早期创始人病毒和SARS-COV-2基因组学的治疗和表征。为了实现他的短暂 他寻求的中期职业目标：a）发展先进的方法论和分析技能 分子流行病学，系统发育分析和生物信息学； b）扩大实时实验室专业知识 高通量的下一代测序以及准确且可靠数量的前病毒储量 推进艾滋病毒治疗研究，c）增强领导能力，特别是在管理大型科学方面 项目，人口级调查以及潜水员研究团队，具有不同领域的专家，组织 领导力和学生研究监督。培训活动将包括正规培训， 课程工作，通过拟议的研究项目进行的实际应用，以及我高度的直接精神训练 经验丰富的精神训练和咨询团队。这些活动将取决于Mentalship团队的优势 并以牢固的协作关系领先的研究机构，并有指导年轻的记录 R01和独立性的调查人员。 研究：该研究旨在引入一种创新的估计艾滋病毒事件的方法，这是非常非常 对于国家艾滋病毒计划 /公共卫生以及艾滋病毒预防研究至关重要，但可以是 昂贵而挑战要做。具体目的是：1）评估调整后的病毒多样性作为潜力 HIV事件的生物标志物。 2）完善真实和假rec的子集的血清学筛查结果 病例和已建立感染的患者（不接受艺术和艺术），通过调整后的病毒多样性。我们将测试 在HIV-1C基因组中最有用的区域内的病毒多样性是否为多重性调整 可以使用传播，重组和病毒复制水平来完善血清学的结果 筛选并提高特异性和灵敏度。我们期望调整后的病毒多样性最多 内容丰富的区域将提高特异性和敏感性，以估计4个子集中的HIV事件的估计 以此目标为目标≥95％。建立一种具有成本效益的算法以估计发病率是 在低资源环境中，公共健康的重要性至关重要。